Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 + KEYTRUDA in Patients with SMARCA4-Mutated Cancers July 17, 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for novel ADC July 17, 2024
First Patient Dosed in Global Randomized Ph 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma July 17, 2024
Positive Interim Ph 2 Monotherapy Expansion Data for IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced July 17, 2024
IND Submission to US FDA for Ph 1/2 study of Silmitasertib (CX-4945) in children and young adults with R/R solid tumors July 17, 2024
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy July 17, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 anti-VISTA Checkpoint Inhibitor July 17, 2024
ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies July 17, 2024
Development of Early-Stage Bispecific T-Cell Engager AMG 794 for Solid Tumors discontinued July 17, 2024
Ph 1/2 dose-escalation study of SP-2577 in combination with azacitidine in adults with MDS and CMML Placed on Partial Hold July 17, 2024
Safety Approval Announced for the First Dose Cohort in Ph 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors July 17, 2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma July 17, 2024
505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection submitted to the FDA for the treatment of somatostatin receptor-positive GEP-NETS July 17, 2024
US FDA grants IND Clearance to Conduct Ph 1/2 Study of JCXH-211 IV as Monotherapy and with Checkpoint Inhibitor in Patients with Advanced Solid Tumors July 17, 2024
HREC Approval and CTN Clearance granted from the TGA to Commence a Ph 1 Clinical Trial for INT2104 for B Cell Malignancies July 17, 2024
Plans for Near-Term Resubmission of NDA for 1L Treatment Option for Unresectable HCC Following Type A FDA Meeting Reported July 17, 2024
